Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 1;13(5):1197-1205.
eCollection 2020.

Expression and clinical significance of Gal-3 and NFκB pathway-related factors in epithelial ovarian carcinoma

Hiu-Mei Luk  1 , Dong-Yan Wang  2 , Ling-Ling Xie  2 , Xun-Yun Liu  2 , Guo-Cai Xu  2 , Huai-Wu Lu  2
Affiliations

Expression and clinical significance of Gal-3 and NFκB pathway-related factors in epithelial ovarian carcinoma

Hiu-Mei Luk et al. Int J Clin Exp Pathol. .

Abstract

Objective: To explore the expression and clinical significance of Gal-3 and NFκB pathway related factors in epithelial ovarian carcinoma cells.

Methods: 99 histologic specimens of epithelial ovarian cancer and 20 normal ovarian histologic specimens were collected, and the expressions of Gal-3, IκB and p65 were detected by immunohistochemistry. Their relationship with clinical characteristics was analyzed.

Results: The expression of Gal-3 and p65 was negatively correlated with the overall survival rate (P<0.05), while the expression of IκB was positively correlated with the overall survival rate (P<0.05). Expression of Gal-3, p65 and IκB were found associated with EOC platinum resistance (P<0.05), and expression of Gal-3 and p65 correlated with pathologic grading (P<0.05). IκB and Gal-3 were associated with the recurrence of EOC (P<0.05). IκB may be related to clinical stage (P<0.05). Multivariate analysis results showed that abnormal expression of Gal-3 may be an independent prognostic risk factors for the drug resistance to platinum-based chemotherapy (95% CI=5.336~34.112, P<0.05). The expression of Gal-3, p65, and IκB can be clinical immunohistochemical indicators that determine the prognosis of EOC, but the amount of Gal-3 expression was related to the epithelial ovarian cancer's pathologic type and overall survival, which suggested that Gal-3 can be used as a prognostic factor in epithelial ovarian cancer.

Conclusion: Targeted therapy of Gal-3 may become an effective potential new method against epithelial ovarian cancer.

Keywords: Galectin-3; IκB; clinical prognosis; epithelial ovarian cancer; p65.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Expression of Gal-3 in normal ovarian epithelium and epithelial ovarian cancer. (×200). A. Normal ovarian epithelial cells; B. Epithelial ovarian cancer cells that are Gal-3 (-); C. Epithelial ovarian cancer cells that are Gal-3 (+); D. Epithelial ovarian cancer cells that are Gal-3 (++).
Figure 2
Figure 2
Expression of p65 in normal ovarian epithelium and epithelial ovarian cancer. (×200). A. Normal ovarian epithelial cells; B. Epithelial ovarian cancer cells that are p65 (-); C. Epithelial ovarian cancer cells that are p65 (+); D. Epithelial ovarian cancer cells that are p65 (++).
Figure 3
Figure 3
Expression of IκB in normal ovarian epithelial and epithelial ovarian cancer. (×200). A. Normal ovarian epithelial cells; B. Epithelial ovarian cancer cells that are IκB (-); C. Epithelial ovarian cancer cells that are IκB (+); D. Epithelial ovarian cancer cells that are IκB (++).
Figure 4
Figure 4
A. Survival curve of IHC positive expression of Gal-3 and survival rate. B. Survival curve of IHC positive expression of p65 and survival rate. C. Survival curve of IHC positive expression of IκB and survival rate.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. - PubMed
    1. Travers M, Brown S, Dunworth M, Holbert C, Casero R, Zahnow C. DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of an ovarian cancer mouse model. In.: AACR. 2019 - PMC - PubMed
    1. Katabuchi H. Frontiers in ovarian cancer science. Springer; 2017.
    1. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213:262–7. - PubMed
    1. Sereni MI, Baldelli E, Gambara G, Deng J, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E 3rd, Pierobon M. Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy. Proteomics. 2015;15:365–73. - PubMed

LinkOut - more resources